An inflammatory transcriptomic signature in psoriasis associates with future cardiovascular events.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 10 10 2022
accepted: 07 02 2023
pmc-release: 01 07 2024
medline: 14 6 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Psoriasis is an inflammatory skin disease associated with increased cardiovascular (CV) risk, whose pathogenesis is not fully known. We identified a transcriptomic signature in psoriasis and investigated its association with prevalent and future risk of a CV event to understand the connection between psoriasis and CV disease (CVD). Psoriasis patients (n = 37) with a history of moderate-severe skin disease without CVD and 11 matched controls underwent whole blood RNA sequencing. This transcriptomic signature in psoriasis versus controls was evaluated in two CVD cohorts: Women referred for cardiac catheterization with (n = 76) versus without (n = 97) myocardial infarction (MI), and patients with peripheral artery disease (n = 106) followed over 2.5 years for major adverse CV or limb events (MACLE). The association between genes differentially expressed in psoriasis and prevalent and incident CV events was assed. In psoriasis, median age was 44 (IQR; 34-51) years, 49% male and ACC/AHA ASCVD Risk Score of 1.0% (0.6-3.4) with no significant difference versus controls. The median psoriasis area and severity index score (PASI) was 4.0 (IQR 2.9-8.2) with 36% on biologic therapy. Overall, 247 whole blood genes were upregulated and 228 downregulated in psoriasis versus controls (p < 0.05), and 1302 genes positively and 1244 genes negatively correlated with PASI (p < 0.05). Seventy-three genes overlapped between psoriasis prevalence and PASI with key regulators identified as IL-6, IL-1β and interferon gamma. In the CVD cohorts, 50 of 73 genes (68%) identified in psoriasis associated with prevalent MI, and 29 (40%) with incident MACLE. Key regulator transcripts identified in psoriasis and CVD cohorts included SOCS3, BCL3, OSM, PIM2, PIM3 and STAT5A. A whole blood transcriptomic signature of psoriasis diagnosis and severity associated with prevalent MI and incident MACLE. These data have implications for better understanding the link between psoriasis, systemic inflammation and CVD.

Sections du résumé

BACKGROUND BACKGROUND
Psoriasis is an inflammatory skin disease associated with increased cardiovascular (CV) risk, whose pathogenesis is not fully known.
OBJECTIVE OBJECTIVE
We identified a transcriptomic signature in psoriasis and investigated its association with prevalent and future risk of a CV event to understand the connection between psoriasis and CV disease (CVD).
METHODS METHODS
Psoriasis patients (n = 37) with a history of moderate-severe skin disease without CVD and 11 matched controls underwent whole blood RNA sequencing. This transcriptomic signature in psoriasis versus controls was evaluated in two CVD cohorts: Women referred for cardiac catheterization with (n = 76) versus without (n = 97) myocardial infarction (MI), and patients with peripheral artery disease (n = 106) followed over 2.5 years for major adverse CV or limb events (MACLE). The association between genes differentially expressed in psoriasis and prevalent and incident CV events was assed.
RESULTS RESULTS
In psoriasis, median age was 44 (IQR; 34-51) years, 49% male and ACC/AHA ASCVD Risk Score of 1.0% (0.6-3.4) with no significant difference versus controls. The median psoriasis area and severity index score (PASI) was 4.0 (IQR 2.9-8.2) with 36% on biologic therapy. Overall, 247 whole blood genes were upregulated and 228 downregulated in psoriasis versus controls (p < 0.05), and 1302 genes positively and 1244 genes negatively correlated with PASI (p < 0.05). Seventy-three genes overlapped between psoriasis prevalence and PASI with key regulators identified as IL-6, IL-1β and interferon gamma. In the CVD cohorts, 50 of 73 genes (68%) identified in psoriasis associated with prevalent MI, and 29 (40%) with incident MACLE. Key regulator transcripts identified in psoriasis and CVD cohorts included SOCS3, BCL3, OSM, PIM2, PIM3 and STAT5A.
CONCLUSIONS CONCLUSIONS
A whole blood transcriptomic signature of psoriasis diagnosis and severity associated with prevalent MI and incident MACLE. These data have implications for better understanding the link between psoriasis, systemic inflammation and CVD.

Identifiants

pubmed: 36924033
doi: 10.1111/jdv.19049
pmc: PMC10334288
mid: NIHMS1890384
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1361-1365

Subventions

Organisme : NCATS NIH HHS
ID : TL1 TR001447
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001445
Pays : United States
Organisme : NHLBI NIH HHS
ID : KL2TR001446
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL114978
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35HL14499
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23HL152013
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL159276
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL139909
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL098129
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL114978
Pays : United States
Organisme : NHLBI NIH HHS
ID : UL1TR001445
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32HL098129
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL152013
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL144993
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL144993
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139909
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001446
Pays : United States
Organisme : NHLBI NIH HHS
ID : TL1TR001447
Pays : United States

Informations de copyright

© 2023 European Academy of Dermatology and Venereology.

Références

Front Cardiovasc Med. 2022 Mar 23;9:818890
pubmed: 35402550
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1340-1351
pubmed: 32131611
Circulation. 2022 Jul 12;146(2):94-109
pubmed: 35652342
Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1521-1533
pubmed: 33657880
Pharmacol Ther. 2015 Jul;151:41-9
pubmed: 25749412
J Am Coll Cardiol. 2018 Jan 2;71(1):53-65
pubmed: 29301628
BMC Cardiovasc Disord. 2020 Mar 13;20(1):133
pubmed: 32169038
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):787-798
pubmed: 30760013
Circ Genom Precis Med. 2018 Dec;11(12):e002387
pubmed: 30562118
J Invest Dermatol. 2022 Jun;142(6):1749-1752.e4
pubmed: 34808233
J Cardiovasc Comput Tomogr. 2021 Jul-Aug;15(4):372-379
pubmed: 33390348
J Am Coll Cardiol. 2021 Apr 6;77(13):1670-1680
pubmed: 33795041
Circ Res. 2016 Nov 11;119(11):1242-1253
pubmed: 27654120
Am J Transl Res. 2021 Mar 15;13(3):1422-1431
pubmed: 33841667

Auteurs

Michael S Garshick (MS)

Department of Medicine, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York City, New York, USA.
Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University School of Medicine, New York City, New York, USA.
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York City, New York, USA.

Tessa J Barrett (TJ)

Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University School of Medicine, New York City, New York, USA.

MacIntosh G Cornwell (MG)

Division of Precision Medicine, New York University School of Medicine, New York City, New York, USA.
Institute for Systems Genetics, New York University School of Medicine, New York City, New York, USA.

Kamelia Drenkova (K)

Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University School of Medicine, New York City, New York, USA.

Jessica Garelik (J)

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York City, New York, USA.

Brittany N Weber (BN)

Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Florencia Schlamp (F)

Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University School of Medicine, New York City, New York, USA.

Caron Rockman (C)

Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York City, New York, USA.

Kelly V Ruggles (KV)

Division of Precision Medicine, New York University School of Medicine, New York City, New York, USA.
Institute for Systems Genetics, New York University School of Medicine, New York City, New York, USA.

Harmony R Reynolds (HR)

Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University School of Medicine, New York City, New York, USA.

Jeffrey S Berger (JS)

Department of Medicine, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York City, New York, USA.
Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University School of Medicine, New York City, New York, USA.
Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York City, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH